Who holds Boston Scientific's stock?
Only 0.71% of the stock of Boston Scientific is held by insiders. 90.22% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for Boston Scientific are expected to grow by 14.91% in the coming year, from $1.61 to $1.85 per share.
What is Boston Scientific's price targets for the next year?
12 brokers have issued 1 year target prices for Boston Scientific's stock. Their forecasts range from $42.74 to $53.00. On average, they anticipate Boston Scientific's stock price to reach $49.90 in the next year. This suggests a possible upside of 17.0% from the stock's current price.
What are the analysts'ratings for Boston Scientific (BSCI)?
12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock.
Where is Boston Scientific located?
Boston Scientific is headquartered at 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. How can I contact Boston Scientific? Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752.
Is Boston Scientific stock a buy?
There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Boston Scientific stock.
Is BSX a buy now?
Needham is very positive about BSX and gave it a "" rating on May 27, 2022. The price target was set to 41.20+2.64....Predicted Opening Price for Boston Scientific Corporation of Thursday, June 2, 2022.Fair opening price June 2, 2022Current price$40.23$39.92 (Undervalued)
Does Boston Scientific stock pay dividends?
Boston Scientific Corporation does not currently pay dividends. As a result, the company also does not offer a dividend reinvestment program (DRIP). Does Boston Scientific have a direct stock purchase plan?
Is BSX a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is BSM a good stock to buy?
The consensus among 3 Wall Street analysts covering (NYSE: BSM) stock is to Strong Buy BSM stock.
What is Boston Scientific most known for?
Boston Scientific is primarily known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries.
Is Boston Scientific public?
Boston Scientific went public through an IPO on May 19, 1992.
Boston Scientific Sees Robust Q2 Sales Across Core Segments
Q2 Revenues in Detail
Boston Scientific posted adjusted earnings per share of 40 cents for the second quarter of 2021, which marked a 400% surge from the year-ago figure. The figure topped the Zacks Consensus Estimate by 8.1% and also exceeded the adjusted earnings per share guidance range of 36 cents to 38 cents.
Segmental Analysis
In the second quarter, revenues rose 70.1% in the United States on a reported basis (same operationally). Revenues were up 59.3% in the Europe, Middle East and Africa region (up 47.1%); 27% in the Asia Pacific zone (up 21.1%); 86.1% in Latin America and Canada (up 73.9%) and 33.8% in emerging markets (up 25.8%).
Margins
Boston Scientific currently has three global reportable segments: Cardiovascular, Rhythm and Neuro plus MedSurg.
Guidance
Gross margin in the second quarter expanded 878 basis points (bps) year over year to 69.3%. There was a 19.5% rise in the cost of products sold to $945 million.
How much money does Boston Scientific make in 2020?
Based on robust second-quarter results, the company increased its full-year 2021 guidance.
Is the BSX up in 2020?
Boston Scientific’s total revenue of $9.9 billion in 2020 compares to $9.8 billion in 2018, while they were down 8% y-o-y. This can be attributed to lower demand for medical devices and consumables, primarily in the first half of 2020, as the spread of Covid-19 resulted in fewer elective surgeries.
What is Boston Scientific?
BSX stock is up 65% from the levels of around $26 it was at on March 23, 2020, underperforming the broader markets with the S&P 500 rising 89% over the same period. The demand for medical devices remained sluggish for the better part of 2020, due to the postponement of elective surgeries, weighing on Boston Scientific’s stock performance.
Is Boston Scientific a buy or sell company?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions;
Does Boston Scientific have dividends?
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 13 buy ratings, 5 hold ratings, and no sell ratings.
